NAMS NewAmsterdam Pharma
- 19.190
- -0.250-1.29%
- 19.190
- 0.0000.00%
NewAmsterdam Pharma News
Express News | NewAmsterdam Pharma Company NV: Patent Extends Obicetrapib's Ip Protection and Exclusivity Until July 2043
Express News | NewAmsterdam Pharma Company NV: Issuance of Composition of Matter Patent for Obicetrapib by United States Patent and Trademark Office
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
-- New patent extends patent term for obicetrapib until July 2043 -- NAARDEN, the Netherlands and MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmst
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
RBC Capital analyst Leonid Timashev maintains $NewAmsterdam Pharma(NAMS.US)$ with a buy rating, and maintains the target price at $31.According to TipRanks data, the analyst has a success rate of 33.3
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NAARDEN, the Netherlands and MIAMI, May 29, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
-- Presentations include new data from OCEAN, ROSE, and ROSE2 Phase 2 clinical trials, demonstrating obicetrapib's impact on key lipid and lipoprotein biomarkers -- -- On track to report topline data
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO), GoodRx Holdings (GDRX) and NewAmsterdam Pharma Company (NAMS)
Analysts' Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Elanco Animal Health (ELAN)
NewAmsterdam Pharma Company (NAMS) Receives a Buy From RBC Capital
EnGene Announces the Election of Paul Hastings and Wouter Joustra to Its Board of Directors
TD Cowen Initiates Coverage On NewAmsterdam Pharma With Buy Rating
TD Cowen analyst Tyler Van Buren initiates coverage on NewAmsterdam Pharma with a Buy rating.
NewAmsterdam Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 — TD Cowen Initiates Coverage On → Buy 03/14/2024 73.81% Scotiabank → $35 Initiates Coverage O
Strong Buy Rating for NewAmsterdam Pharma on Obicetrapib's Promising Efficacy and Market Potential
NewAmsterdam Pharma Company (NAMS) Receives a Buy From Scotiabank
NewAmsterdam Pharma Q1 EPS $(1.06) Vs $(0.51) YoY
First Quarter Financial ResultsCash Position: As of March 31, 2024, NewAmsterdam recorded cash of $481.1 million, compared to $340.5 million as of December 31, 2023. The increase in cash is primarily
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
08:04 AM EDT, 05/09/2024 (MT Newswires) -- Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
NewAmsterdam Pharma 1Q Rev $1.4M >NAMS
NewAmsterdam Pharma 1Q Rev $1.4M >NAMS
Express News | NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Pha
10-Q: Quarterly report
Analysis
Price Target
No Data
